The Antiobesity Drugs Market is all set to be in the driver’s seat shortly. Technology adoption once looked upon as a costly endeavor, is slated to witness a drastic transformation in the form of granular applications. Technologies like DevOps and AIOps are constructively disrupting the healthcare IT sector and are expected to create wonders in this regard in the upcoming period.
According to World Health Organization (WHO), obesity refers a disorder of accumulation of excessive fat that can impair health. Body Mass Index (BMI) is an index of weight for height, which is a measure for classifying obesity and overweight. According to WHO, BMI greater than or equal to 30 is consider as an Obese.
Anti-obesity drugs refers the drugs that reduces or control the body weight by either reducing the appetite or increasing the absorption of calories. The fundamental treatment for obesity is to control over unhealthy diet, and regular exercise, as although anti-obesity drugs are available in the market, their usefulness is restricted to maintain weight rather than cure.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/8884
Obesity is a risk factor for development of several chronic diseases such as coronary heart diseases, hypertension, metabolic disorders such as diabetes, and others. Hence, need to control by proper medication, diet, and exercise. Bariatric surgery is an also option for weight loss for BMI more than 40. However, lifelong changes in eating and exercise habits are necessary after surgery.
Global anti-obesity drugs market segmented by approved drugs: buproprion and naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), and liraglutide (Saxenda). Geographically, global anti-obesity drugs market segmented into North America, Europe, Asia Pacific, Latin America, and rest of the World.
Presently, North America holds largest share of the market due to increasing obese population. For instance, according to Centers for Disease Control and Prevention (CDC), more than one third of U.S. population is obese in 2014. However, Asia Pacific expected to grow at highest rate due to increasing demand of drugs, and awareness regarding risk associated with obesity. Additionally, sedentary lifestyle, and unhealthy diet would expect to increase the number of obese people during forecast period.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/8884
Increase in incidence of obesity is majorly due to lack of physical activity, lack of sleep, and high calorie diet. Additionally, family history, and consumption of certain medicines such as antidepressant, diabetes agent also play a major role in obesity. For instance, according to World Health Organization (WHO), about 13% of world’s population were obese in 2014.
Additionally, according to WHO, in emerging countries the rate of increase of childhood obesity has been more than 30% higher than that of developed countries. However, several side effects such as risk of psychiatric disorder, non-fatal myocardial infraction, or stroke could affect the market negatively albeit. Hence, development of medicines with lesser side effects with chronic use, and increasing focus on developing countries market can help to boost the market.
Recently, in September 2014 U.S. FDA approved Contrave, an extended release tablet for chronic weight management. Contrave is a combination of two already FDA-approved drugs, naltrexone and bupropion, and distributed by Takeda Pharmaceuticals America Inc. However, the drug is acting by very different mechanism of mesolimbic pathway. Hence, approval of such a drugs in the market could expect to surge the market growth.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/8884
Key players in the global anti-obesity market are Arena Pharmaceuticals, Bristol-Myers Squibb, Alizyme, Boehringer Ingelheim GmbH, Eisai Company, Ltd., F. Hoffmann-La Roche, GlaxoSmithKline plc, Bayer AG, Inc., Novo Nordisk, and Norgine Pharmaceuticals Ltd. Additionally, some other company includes Orexigen Therapeutics, Pfizer, Inc., Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Inc., and Zafgen.
About Us: Persistence Market Research
Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Sales – email@example.com
Website – https://www.persistencemarketresearch.com
Why pay for news and opinions when you can get them for free?
Subscribe for free now!
By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
BUSINESS2 days ago
The Impact of Product Complexity and Waste in Manufacturing
BUSINESS4 days ago
Baer says exposure to single group tops 600 million francs, as Signa crisis deepens
FINANCE4 days ago
BoE’s Bailey says getting inflation to 2% will be ‘hard work’
NEWS2 days ago
Swedish property problems could accelerate price drops in Denmark, central bank says